Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.

MLA

John, Jessy, et al. “Divergent Outcomes of Anti-PD-L1 Treatment Coupled with Host-Intrinsic Differences in TCR Repertoire and Distinct T Cell Activation States in Responding versus Non-Responding Tumors.” Frontiers in Immunology, vol. 13, Oct. 2022, pp. 01-21. EBSCOhost, https://doi.org/10.3389/fimmu.2022.992630.

APA

John, J., Woolaver, R. A., Popolizio, V., Chen, S. M. Y., Huaibin Ge, Krinsky, A. L., Vashisht, M., Kramer, Y., Zhangguo Chen, & Jing H. Wang. (2022). Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Frontiers in Immunology, 13, 01-21. https://doi.org/10.3389/fimmu.2022.992630

Chicago

John, Jessy, Rachel A. Woolaver, Vince Popolizio, Samantha M. Y. Chen, Huaibin Ge, Alexandra L. Krinsky, Monika Vashisht, Yonatan Kramer, Zhangguo Chen, and Jing H. Wang. 2022. “Divergent Outcomes of Anti-PD-L1 Treatment Coupled with Host-Intrinsic Differences in TCR Repertoire and Distinct T Cell Activation States in Responding versus Non-Responding Tumors.” Frontiers in Immunology 13 (October): 01-21. doi:10.3389/fimmu.2022.992630.